skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2];  [3];  [4];  [1];  [1];  [1];  [1];  [1];  [1]
  1. Division of Radiation Medicine, Proton Therapy, Paul Scherrer Institut, Villigen (Switzerland)
  2. Department of Radiation Oncology, University of Muenster, Muenster (Germany)
  3. Department of Paediatric Oncology, University Children's Hospital, Zurich (Switzerland)
  4. Department of Anaesthesia, University Children's Hospital, Zuerich (Switzerland)

Purpose: Radiotherapy plays a major role in the treatment strategy of childhood sarcomas. Consequences of treatment are likely to affect the survivor's quality of life significantly. We investigated the feasibility of spot-scanning proton therapy (PT) for soft tissue tumors in childhood. Methods and Materials: Sixteen children with soft tissue sarcomas were included. Median age at PT was 3.3 years. In 10 children the tumor histology was embryonal rhabdomyosarcoma. All tumors were located in the head or neck, parameningeal, or paraspinal, or pelvic region. In the majority of children, the tumor was initially unresectable (Intergroup Rhabdomyosarcoma Study [IRS] Group III in 75%). In 50% of children the tumors exceeded 5 cm. Fourteen children had chemotherapy before and during PT. Median total dose of radiotherapy was 50 cobalt Gray equivalent (CGE). All 16 children were treated with spot-scanning proton therapy at the Paul Scherrer Institute, and in 3 children the PT was intensity-modulated (IMPT). Results: After median follow-up of 1.5 years, local control was achieved in 12 children. Four children failed locally, 1 at the border of the radiation field and 3 within the field. All 4 children died of tumor recurrence. All 4 showed unfavorable characteristic either of site or histopathology of the tumor. Acute toxicity was low, with Grade 3 or 4 side effects according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) criteria occurring in the bone marrow only. Conclusions: Proton therapy was feasible and well tolerated. Early local control rates are comparable to those being achieved after conventional radiotherapy. For investigations on late effect, longer follow-up is needed.

OSTI ID:
20944693
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 67, Issue 2; Other Information: DOI: 10.1016/j.ijrobp.2006.08.053; PII: S0360-3016(06)02803-3; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Spot Scanning Proton Therapy in the Curative Treatment of Adult Patients With Sarcoma: The Paul Scherrer Institute Experience
Journal Article · Thu Nov 01 00:00:00 EDT 2007 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20944693

Postoperative Spot-Scanning Proton Radiation Therapy for Chordoma and Chondrosarcoma in Children and Adolescents: Initial Experience at Paul Scherrer Institute
Journal Article · Thu May 01 00:00:00 EDT 2008 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20944693

Patterns of Failure in Pediatric Rhabdomyosarcoma After Proton Therapy
Journal Article · Thu Dec 01 00:00:00 EST 2016 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20944693